WO2000018429A3 - Vaccin a base d'haemophilus somnus attenue - Google Patents

Vaccin a base d'haemophilus somnus attenue Download PDF

Info

Publication number
WO2000018429A3
WO2000018429A3 PCT/US1999/022107 US9922107W WO0018429A3 WO 2000018429 A3 WO2000018429 A3 WO 2000018429A3 US 9922107 W US9922107 W US 9922107W WO 0018429 A3 WO0018429 A3 WO 0018429A3
Authority
WO
WIPO (PCT)
Prior art keywords
somnus
vaccine
expression
attenuated
vaccine based
Prior art date
Application number
PCT/US1999/022107
Other languages
English (en)
Other versions
WO2000018429A2 (fr
Inventor
Lynette B Corbeil
Elizabeth J Ziegler
Jerry D Sanders
Original Assignee
Univ California
Lynette B Corbeil
Elizabeth J Ziegler
Jerry D Sanders
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Lynette B Corbeil, Elizabeth J Ziegler, Jerry D Sanders filed Critical Univ California
Priority to AU61605/99A priority Critical patent/AU6160599A/en
Priority to CA002347278A priority patent/CA2347278C/fr
Priority to US09/787,964 priority patent/US6770273B1/en
Publication of WO2000018429A2 publication Critical patent/WO2000018429A2/fr
Publication of WO2000018429A3 publication Critical patent/WO2000018429A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une méthode qui permet de protéger le bétail de maladies telles que la septicémie, la pneumonie ou l'avortement en l'immunisant au moyen d'un vaccin à base de H. somnus. Elle concerne également des isolats naturels de souches de H. somnus qui possèdent d'importantes caractéristiques dudit vaccin, notamment le fait qu'elles peuvent être tuées dans un sérum bovin contenant du complément, l'absence d'expression des protéines liant les immunoglobulines, l'expression d'antigènes protecteurs et une faible libération d'endotoxine durant leur croissance. On peut aussi préparer, par des techniques de recombinaison d'ADN, des vaccins à base de H. somnus, possédant d'autres caractéristiques en plus de celles indiquées ci-dessus, à partir d'isolats naturels de porteurs asymptomatiques ou d'organismes pathogènes.
PCT/US1999/022107 1998-09-25 1999-09-24 Vaccin a base d'haemophilus somnus attenue WO2000018429A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU61605/99A AU6160599A (en) 1998-09-25 1999-09-24 Vaccine based on attenuated (haemophilus somnus)
CA002347278A CA2347278C (fr) 1998-09-25 1999-09-24 Vaccin a base d'haemophilus somnus attenue
US09/787,964 US6770273B1 (en) 1998-09-25 1999-09-24 Vaccine based on attenuated Haemophilus somnus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10176098P 1998-09-25 1998-09-25
US60/101,760 1998-09-25

Publications (2)

Publication Number Publication Date
WO2000018429A2 WO2000018429A2 (fr) 2000-04-06
WO2000018429A3 true WO2000018429A3 (fr) 2000-07-06

Family

ID=22286272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/022107 WO2000018429A2 (fr) 1998-09-25 1999-09-24 Vaccin a base d'haemophilus somnus attenue

Country Status (3)

Country Link
AU (1) AU6160599A (fr)
CA (1) CA2347278C (fr)
WO (1) WO2000018429A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597386B2 (en) * 2012-04-05 2017-03-21 Boehringer Ingelheim Vetmedica, Inc. Outer membrane proteins of Histophilus somni and methods thereof
WO2015148687A2 (fr) * 2014-03-25 2015-10-01 Merial, Inc. Compositions immunologiques contenant des souches de histophilus somni atténuées

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CORBEIL L B ET AL: "Characterization of immunodominant surface antigens of Haemophilus somnus.", INFECTION AND IMMUNITY, (1991 DEC) 59 (12) 4295-301., XP002137020 *
GOGOLEWSKI, RONALD P. ET AL: "Protective ability of antibodies against 78- and 40-kilodalton outer membrane antigens of Haemophilus somnus", INFECT. IMMUN. (1988), 56(9), 2307-16, XP002137019 *
YANG Y F ET AL: "Apoptosis: a possible tactic of Haemophilus somnus for evasion of killing by bovine neutrophils?.", MICROBIAL PATHOGENESIS, (1998 JUN) 24 (6) 351-9., XP000891692 *

Also Published As

Publication number Publication date
CA2347278C (fr) 2007-07-17
AU6160599A (en) 2000-04-17
CA2347278A1 (fr) 2000-04-06
WO2000018429A2 (fr) 2000-04-06

Similar Documents

Publication Publication Date Title
WO1995029193A3 (fr) Antigenes du melanome
CA2290485A1 (fr) Procede de production de proteines non immunogenes
GB2303855B (en) Helicobacter pylori antigenic protein preparation and immunoassays
EP0835315A4 (fr) Vaccin contre le virus du syndrome dysgenesique respiratoire porcin
KR910000183A (ko) 재조합 포자충증 백신
EP2311952A3 (fr) Anticorps dirigé vers MART-1 protéine et ses fragments
EP0835133A4 (fr) Compositions recombinantes et compositions combinees de virus de la rage et de la variole, et leurs utilisations
CA2103887A1 (fr) Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
EP0855918A4 (fr) Interleukine-15 du poulet et ses utilisations
CA2096159A1 (fr) Peptides induisant des anticorps qui neutralisent les isolats de vih-1 divergents sur le plan genetique
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
NO329875B1 (no) Isolert DNA-sekvens som koder for svinereproduktive- og respiratoriske syndromvirus (PRRSV), en sammensetning omfattende polypeptidene kodet av denne, en sammensetning for indusering av antistoffer mot PRRSV, anvendelse av sammensetning for fremstilling av vaksine og fremgangsmate for a skille PRRSV-stamme ISU-55 fra andre PRRSV-stammer.
DK0957935T3 (da) Chlamydia-vacciner og immunogene præparater indeholdende et ydre membran-antigen samt fremgangsmåde til fremstilling deraf
EP0866133A3 (fr) Un vaccin de la groupe B de Streptococcus
WO2002026250A3 (fr) Vaccins ameliores pour l'ileite proliferante et procedes de fabrication et d'utilisation correspondants
PL303482A1 (en) Vaccine against infection with streptococcus suis, streptococcus suis polypeptide and method of preparing such vaccine
DE69737413D1 (en) Bakterioferritin aus helicobacter pylori
WO1996021734A3 (fr) Antigenes p15 et tyrosinase du melanome et leur utilisation dans des procedes diagnostiques et therapeutiques
GB9401987D0 (en) Modified nucleic acid
ATE162550T1 (de) Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
WO1996018646A3 (fr) Peptides de proteines de choc thermique et procedes de modulation d'une maladie auto-immune du systeme nerveux central
AU6995291A (en) Recombinant coccidiosis vaccines -5-7 eimeria surface antigen
MX9801089A (es) Proteina hibrida que comprende epitopes estimulantes de celula auxiliar t y epitopes de celula b de la proteina de membrana externa mayor chlamydia trachomatis y su uso como vacuna.
EP0348725A3 (fr) Epitode spécifique de l'espèce de chlamydia trachomatis et les anticorps le reconnaissant
WO2000018429A3 (fr) Vaccin a base d'haemophilus somnus attenue

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2347278

Country of ref document: CA

Ref country code: CA

Ref document number: 2347278

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09787964

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase